Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 6/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14290829 | 1.00 | CTSK (0.49) | CTSKNFKB1NFKB2RELACYP1A2 | |
| SCHEMBL10164321 | 1.00 | CTSK (0.49) | CTSKNFKB1NFKB2RELACYP1A2 | |
| SCHEMBL1261146 | 0.92 | CTSK (0.50) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL13829039 | 0.92 | CTSK (0.50) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL12648034 | 0.92 | CTSK (0.50) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL16330414 | 0.88 | CTSK (0.54) | CTSKNFKB1NFKB2RELACYP1A2 | |
| SCHEMBL17884307 | 0.88 | CTSK (0.54) | CTSKNFKB1NFKB2RELACYP1A2 | |
| SCHEMBL23135898 | 0.87 | CYP1A2 (0.58) | CTSKCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL614515 | 0.85 | SMN1; SMN2 (0.48) | CTSKNFKB1NFKB2RELACYP1A2 | |
| SCHEMBL1433271 | 0.85 | SMN1; SMN2 (0.48) | CTSKNFKB1NFKB2RELACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117615760-A | Extended dosage regimen for integrin inhibitors | 普利安特治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-115989235-A | Methods of treating respiratory diseases using amino acid compounds | 普利安特治疗公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-114173803-A | Dosage forms and regimens for amino acid compounds | 普利安特治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-112135612-A | Amino acid compounds and methods of use | 普利安特治疗公司 | 2020-12-25 | — | — | CN | disclosed |
| EP-3689353-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3099300-B1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-3150586-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3099300-A1 | ARYL LACTAM KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160333006-A1 | ARYL LACTA KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-17 | — | — | US | disclosed |
| EP-2880032-B1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015116060-A1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
| EP-2880032-A1 | ARYL LACTAM KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-06-10 | — | — | EP | disclosed |
| US-8901305-B2 | Aryl lactam kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140038999-A1 | Aryl Lactam Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2014-02-06 | — | — | US | disclosed |
| WO-2014022167-A1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2011041713-A2 | PIPERAZINYL ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038999-A1 | Aryl Lactam Kinase Inhibitors | AAK1, ADCK1, ANKK1 | CTSK 1026/4885NFKB1 972/4885NFKB2 817/4885 |
| US-20160333006-A1 | ARYL LACTA KINASE INHIBITORS | AAK1, NCK1, ANKK1 | CTSK 839/4885NFKB1 1258/4885NFKB2 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.